Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses advances in treatment modalities to reduce the risk of graft-versus-host disease (GvHD) and other life-threatening complications following hematopoietic stem cell transplantation (HSCT). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.